Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	859,015	457,800	533,530	849,695	966,222	637,614
Cash & Short-Term Investments	859,015	457,800	533,530	849,695	966,222	637,614
Cash Growth	170.09%	-14.19%	-37.21%	-12.06%	51.54%	-9.18%
Accounts Receivable	700,537	612,439	575,431	617,517	707,487	670,708
Other Receivables	20,519	85,171	106,262	106,860	105,227	114,213
Receivables	721,056	697,610	681,693	724,377	812,714	784,921
Inventory	1,206,431	1,209,869	986,457	853,167	753,881	759,599
Other Current Assets	267,511	193,301	196,276	166,403	180,076	287,298
Total Current Assets	3,054,013	2,558,580	2,397,956	2,593,642	2,712,893	2,469,432
Property, Plant & Equipment	1,887,620	1,989,777	1,691,229	1,582,800	1,453,917	1,386,370
Long-Term Investments	15,628	89,831	99,174	96,579	112,468	107,334
Goodwill	5,160,112	5,410,067	4,790,723	4,407,749	4,033,917	4,012,528
Other Intangible Assets	3,770,620	4,274,682	4,269,657	3,818,544	3,909,106	4,171,361
Long-Term Deferred Tax Assets	338,304	393,865	366,003	362,539	353,769	308,102
Other Long-Term Assets	346,703	391,990	343,008	316,165	336,223	365,967
Total Assets	14,573,000	15,108,792	13,957,750	13,178,018	12,912,293	12,821,094
Accounts Payable	413,335	319,955	307,453	295,934	232,105	211,627
Short-Term Debt	-	317,251	40,256	285	69	5,014
Current Portion of Long-Term Debt	624,101	50,000	299,344	203,708	22,084	581,803
Current Portion of Leases	-	66,208	59,623	53,877	50,187	41,084
Current Income Taxes Payable	141,439	109,906	232,377	200,918	145,203	182,738
Other Current Liabilities	1,208,362	1,449,783	1,542,887	1,391,008	1,323,528	1,153,632
Total Current Liabilities	2,387,237	2,313,103	2,481,940	2,145,730	1,773,176	2,175,898
Long-Term Debt	4,427,092	4,476,501	4,042,741	4,141,418	4,613,218	4,506,487
Long-Term Leases	558,201	553,431	419,728	411,361	386,225	328,375
Long-Term Deferred Tax Liabilities	46,619	113,777	270,620	451,511	542,852	710,147
Other Long-Term Liabilities	96,367	234,093	260,456	198,628	260,788	216,084
Total Liabilities	7,651,403	7,834,787	7,603,079	7,494,495	7,735,116	8,093,608
Common Stock	1,694,660	1,676,596	1,676,345	1,676,263	1,668,145	1,668,123
Additional Paid-In Capital	1,738,145	1,747,414	1,728,830	1,708,873	1,688,424	1,680,287
Retained Earnings	1,431,684	1,391,203	1,541,146	1,479,716	1,509,906	1,369,972
Treasury Stock	-24,829	-51,259	-100,317	-116,007	-59,552	-87,463
Comprehensive Income & Other	2,081,094	2,509,310	1,508,118	934,174	366,114	92,564
Total Common Equity	6,920,754	7,273,264	6,354,122	5,683,019	5,173,037	4,723,483
Minority Interest	843	741	549	504	4,140	4,003
Shareholders' Equity	6,921,597	7,274,005	6,354,671	5,683,523	5,177,177	4,727,486
Total Liabilities & Equity	14,573,000	15,108,792	13,957,750	13,178,018	12,912,293	12,821,094
Total Debt	5,609,394	5,463,391	4,861,692	4,810,649	5,071,783	5,462,763
Net Cash (Debt)	-4,750,379	-5,005,591	-4,328,162	-3,960,954	-4,105,561	-4,825,149
Net Cash Per Share	-2981.41	-3167.41	-2757.02	-2511.43	-2609.13	-3080.79
Filing Date Shares Outstanding	1,585	1,569	1,555	1,550	1,563	1,558
Total Common Shares Outstanding	1,585	1,569	1,555	1,550	1,563	1,558
Working Capital	666,776	245,477	-83,984	447,912	939,717	293,534
Book Value Per Share	4365.91	4635.57	4087.49	3665.61	3308.93	3032.22
Tangible Book Value	-2,009,978	-2,411,485	-2,706,258	-2,543,274	-2,769,986	-3,460,406
Tangible Book Value Per Share	-1267.98	-1536.94	-1740.89	-1640.44	-1771.82	-2221.39
Land	-	105,845	98,227	98,654	95,235	96,629
Buildings	-	937,156	826,523	763,460	670,609	673,562
Machinery	-	1,124,798	976,111	893,628	804,452	773,860
Construction In Progress	-	278,689	207,400	154,960	140,159	124,164

Source: S&P Capital IQ. Standard template. Financial Sources.